Somahlution is a privately-held global biotechnology company headquartered in Jupiter, Florida that develops and markets innovative products that address critical unmet medical needs, using breakthrough technologies to advance human health. Somahlution’s portfolio of products are designed to reduce the disease burden of Ischemia Reperfusion Injury (IRI) and address unmet needs for tissue grafting, organ transplant and other surgical indications. The products are based on a proprietary and innovative platform technology called GALA that is licensed from The U.S. Department of Veterans Affairs.

Using the GALA platform technology, the Company has developed a portfolio of products including a first-in-class product, DuraGraft®. DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure. DuraGraft enhances CABG outcomes by significantly reducing major cardiac events such as repeat revascularization, myocardial infarction and MACE.

DuraGraft was launched in Europe and other global markets in 2015 for CABG and Peripheral Bypass Indications and is expected to launch for use in CABG surgery in the United States in 2017.

  • Experienced Team

    Somahlution has assembled an experienced and accomplished executive team, employees, advisors and consultants to advance its mission through product and clinical development, regulatory approval and launch.

    Experienced Team
  • Competitive Advantages

    Somahlution’s products are either first-in-class and/or designed for superior performance as compared to standard of care products. Therefore, Somahlution anticipates rapid penetration of its products in the marketplace.

    Competitive Advantages
  • Market Expansion

    Through licensing and partnering, Somahlution intends to expand its markets for DuraGraft through collaborations with large pharma, medical device companies and/or other regional firms to address markets outside of Europe, North America and Australia. The company has currently entered into partnership-distribution agreements with regional players in South East Asia, Latin America and Indo-China.

    Market Expansion
  • Rich Product Portfolio

    The Company’s portfolio of products based on GALA platform technology (DuraGraft) and GALA-based SOM products for organ transplantation provides for niche and unique market opportunities, addressing critical unmet clinical-medical needs.

    Rich Product Portfolio